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The Principles behind Targeted 
Therapy for Cancer Treatment
Wabel AL-Busairi and Maitham Khajah
Abstract
The advent of molecular and genetic advancement in the field of oncology 
research has led to a shift in the treatment of various forms of cancer from traditional 
chemotherapeutics to targeted therapy. The principle behind targeted therapy is 
utilizing therapeutics designed to interfere with specific molecules that have a rela-
tively specific or higher expression profile in cancer cells and are critical for cancer 
growth and progression. These were designed as mechanistic therapeutics in the form 
of small molecules and monoclonal antibodies. Currently, they have been modified 
to incorporate passive or active targeting delivery systems to improve their specific 
distribution and enhance cytotoxicity towards cancer cells while simultaneously 
reducing their systemic toxicity profile. Passive targeting employs encapsulated deliv-
ery systems to take advantage of the enhanced permeation and retention effect of the 
tumor microenvironment, while active targeting relies on receptor mediated interac-
tions, such as cell surface ligands conjugated to the therapeutic moiety. A synergistic 
strategy for cancer therapy is evolving, where precision medicine acts as a diagnostic 
prerequisite for targeted therapy via prognostic biomarkers and tumor genotyping. 
Despite the plethora of research undertaken in targeted therapy, limited numbers 
were approved for clinical use, and significant challenges remain to be addressed.
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1. Introduction
Various forms of cancers remain to be the leading cause of mortality worldwide. 
A recent article estimated the incidence and mortality of cancer in 20 world regions 
(using the GLOBOCAN 2018 estimates), and suggested approximately 18 million 
new cases and 9.6 million deaths in the year of 2018. Lung cancer was most com-
monly diagnosed, and the leading cause of cancer-related death followed by breast, 
prostate, colorectal, stomach, and liver cancer [1]. Although surgery and radiation 
therapy are considered the primary treatment for localized forms of cancers, che-
motherapeutic agents must be used when cancer cells metastasize to the regional 
lymphatic vessels and bloodstream. This placed more emphasis on the development 
of drugs and biological molecules as chemotherapeutic agents to minimize the risk of 
cancer metastasis to other organs, which will lead to organ failure and death [2, 3].
2. Traditional chemotherapeutic agents
The era of cancer drug development was pioneered in the 1940s after using nitro-
gen mustard as a toxic treatment for cancer [2]. Traditional chemotherapeutic agents 
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mediate cytotoxicity by interrupting processes or inhibiting molecules required for 
rapid cellular division and DNA synthesis at the cell cycle level. They are categorized 
as either cell cycle specific (they target a specific phase in the cell cycle) or cell cycle 
non-specific (they target all cell cycle phases) agents [4]. Their main disadvantage 
relies on their relative non-selectivity in targeting rapidly dividing non-cancerous 
cells such as hair follicles, bone marrow and gastrointestinal epithelial cells. This 
commonly manifests as serious adverse effects on patients such as hair loss, anemia, 
infections (due to low white blood cell count), infertility, nausea and vomiting. As a 
result, the effective therapeutic dose is unattained and the efficacy of conventional 
chemotherapeutic agents is compromised. This is commonly experienced in the 
clinic, when a chemotherapy regimen is administered for a delimited period, but 
the dose has to be reduced or treatment is postponed as a safety precaution despite 
tumor responsiveness [5, 6]. Furthermore, many conventional chemotherapeutics 
do not accumulate in the tumor mass at effective therapeutic concentrations, thereby 
cannot effectively inhibit their proliferation and metastasis. This is particularly true 
at the core micro-regions of tumors; due to the disorganized intratumoral vascula-
ture and high interstitial fluid pressure as a consequence of aberrant angiogenesis 
and poor lymphatic drainage. Some types of cancers such as brain gliomas, are also 
difficult to reach with traditional chemotherapeutics, as they are unable to penetrate 
the blood brain barrier. These factors play a paramount role in drug resistance [7]. 
Chemotherapeutic agents with inadequate bioavailability and pharmacokinetic pro-
files are more inclined to metabolism and excretion before reaching cancerous cells 
[8]. Cancerous cells not killed during treatment are likely to acquire resistance and 
eventually lead to a more aggressive form of tumors with high probability of organ 
damage and death [4]. In addition, various oncogenes and oncoproteins in a variety 
of cancers are able to inactivate chemotherapeutic agents and/or eliminate them from 
tumor cells (e.g., through the activity of multi-drug resistance; MDR) [7, 8].
Mechanisms that mediate resistance have been studied abundantly, and many 
are attributed to mutations of various oncogenes. They include altered transport 
of chemotherapeutics across the plasma membrane by ATP-dependent multi-
drug transporters or upregulation of multidrug resistant gene, which encodes 
P-glycoprotein responsible for xenobiotic efflux out of cells [7]. Another example 
are defects in the apoptotic pathways leading to a loss of function in the tumor 
suppressor gene p53, allowing cells with damaged DNA to continue replicating 
and hence be unresponsive to DNA damaging effects of chemotherapeutics such 
as pyrimidine antagonist 5-fluorouracil and the mitotic spindle inhibitor paclitaxel 
[7, 8]. Enhanced action of DNA repair proteins in cancer cells also contributes to 
acquired forms of chemoresistance. This phenomenon has been observed with 
chemotherapeutics causing direct damage to the structural integrity of DNA such 
as intercalating agents like cisplatin and alkylating agents [7, 8]. While chemothera-
peutics that mediate their action by binding to the topoisomerase-DNA complex 
to prevent DNA synthesis, such as doxorubicin, etoposide and camptothecin are 
rendered inactive by the altered activity of topoisomerase I and II, hence resistance 
facilitates the repair of topoisomerase-DNA complex [7, 8].
The design and development of conventional chemotherapeutics is prehistoric 
relative to recent findings in the complex cancer pathophysiology and tumor 
microenvironment. Recently, the heterogeneity of tumors is widely established as a 
challenge for traditional forms of cancer therapy. It is recognized to result from the 
higher genetic instability of uncontrolled cell division; increasing the likelihood of 
multiple mutations and replications errors. Ultimately it manifests as phenotypic 
and functional tumor heterogeneity that can occur within and between tumors 
[9]. Dynamic and regional variations in the tumor microenvironment in blood, 
lymphatic vasculature, extracellular matrix metalloproteases and cellular secretions 
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in the tumor stroma may greatly influence the diverse development of cancer cells. 
Furthermore, a distinct population of cells within tumors termed cancer stem cells 
with a capacity for self-renewal and differentiation are recognized to be responsible 
for cancer relapse, also contributing to this factor [9]. The heterogeneity of tumors 
has proved to be a limitation to treatment with traditional chemotherapeutics and 
restricts their use for a variety of cancer types, it also supports intrinsic resistance to 
cancer therapy. In order to combat these limitations which ultimately lead to cancer 
progression and reduces the survival rates of patients, more selective/targeted/effi-
cient therapies are required. This lead to the discovery of new agents which are based 
on the investigation of molecular behavior, biomarkers, oncogenes and biological 
pathways used by cancer cells to determine specific key distinctions between them 
and normal cells, that are responsible for tumor cell proliferation, survival and 
progression. Once identified these distinctions are targeted “with precision” while 
sparing normal cells. This concept has been renowned the “magic bullet” of cancer 
therapy and is the fundamental principle behind targeted cancer therapy [10].
The advent of targeted cancer therapy was established by the development of 
molecular targeted therapeutics, also recognized as mechanistic or direct-targeted 
cancer therapy [11]. This strategy utilizes small molecules or monoclonal antibodies 
(MAb) designed to interfere with specific molecular targets that have a relatively 
specific or higher expression profile in cancer cells and are critical for their growth 
and metastasis [11, 12]. Small molecule targeted therapies are usually low molecular 
weight organic compounds (<800 Daltons), that have a higher rate of cell entry 
relative to MAb, and so are designed to interfere with the expression/activity of 
intracellular signaling molecules [4]. On the other hand, MAbs generally have high 
binding affinities to extracellular domains expressed on cancer cells and are com-
monly designed to target the extracellular surface of cancerous cells; they mediate 
their mode of action through receptor ligand interactions [4].
3. Types of targeted therapies
Various types of molecular target mechanisms have been identified for cancer 
therapy; these include signal transduction inhibitors, hormone therapies, gene 
expression modulators, apoptosis inducers, angiogenesis inhibitors, immunothera-
pies and toxin delivery molecules. Many of these mechanisms overlap and with the 
advancement in cancer research a single anticancer therapeutic agent can encom-
pass multiple molecular mechanisms. This is further elaborated in the subsequent 
paragraphs of this chapter.
3.1 Signal transduction inhibitors
Signal transduction is considered the link between a ligand mediated activation 
of a receptor to the resultant cellular responses such as metabolism, gene expres-
sion, cell division and apoptosis, and motility/migration, etc. [13]. Hence it is a 
vital route to explore for molecular-targeted therapies. Many remarkably successful 
agents have been developed under this category, owning to the understanding of 
signal transduction pathways in cancer cells. Genetic and epigenetic changes that 
occur in cancer cells lead to uncontrolled cellular functions (such as proliferation) 
in part through aberrant/modulated activity of various signaling and metabolic 
networks [13]. While normal cells have redundant overlapping pathways that allow 
for alternative signal transduction when one is inhibited, cancer cells have placed 
more emphasis on distinct signaling pathways owning to various mutations [13]. As 
a result, they have a diminished signaling network with “hyper-active” pathways 
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to sustain cell proliferation and survival [13]. These “hyper-active” pathways are 
reflected in the overexpression of certain proteins in cancer cells. Together, these 
characteristics make cancerous cells more sensitive to stress and mutagens [13]. 
This forms the basis of signal transduction targeted molecular therapy. Therefore, 
theoretically depriving cancer cells from essential signaling elements needed for 
survival will lead to apoptosis and growth arrest [13]. Furthermore, some cancer 
cells are “addicted” to specific signaling proteins, as they are dependent on their 
activity for survival; a prime example is in chronic myeloid leukemia (CML) cancer. 
CML cells particularly in the early stage of cancer have absolute dependency on the 
kinase activity of Bcr-Abl fusion protein [13]. Bcr-Abl fusion protein results from 
an abnormal translocation in the Philadelphia chromosome (Ph) in 95% of CML 
patients. Fusion of Bcr and Abl genes leads to constitutive activation of Bcr-Abl 
tyrosine kinase, causing CML cells to grow and divide excessively [13]. Protein 
kinases are enzymes that regulate the biological activity of proteins by phosphoryla-
tion of specific amino acids with adenosine triphosphate (ATP) to induce confor-
mational changes from the inactive to the active form [14]. Protein Kinases have 
been implicated in cell proliferation and many have transforming capacity making 
them oncoproteins [14]. Consequently, protein kinases have been extensively 
studied as a signal transduction inhibitor pathway in targeted drug therapy [13–15].
One of the most successful molecular targets of anticancer agents is the protein 
tyrosine kinase inhibitor imatinib (Gleevec®), for the treatment of Ph positive 
CML [4, 9, 10, 12–15]. Its success is based on the extreme “addiction” of CML cells 
to Bcr-Abl fusion pathway. Imatinib is designed as an ATP mimic which acts by 
blocking tyrosine phosphorylation, it competitively binds to the ATP binding site 
on Bcr-Abl fusion protein to disrupt tyrosine kinase activity [14]. It is reported to 
have up to 80% response rate in Ph positive CML patients [14]. This protein kinase 
inhibitor is also indicated for a subset of patients with gastrointestinal stromal 
(GIST) tumors, which have activated point mutations in the c-Kit proto-oncogene 
or platelet derived growth factor receptor (PDGFR)-α kinase [4, 12, 13].  
Constitutive activation of kinase, as in the Bcr-Abl fusion protein, inhibits apop-
tosis and stimulates cell proliferation [3, 12, 13]. Although imatinib is a highly 
selective agent, it has been responsive for the inhibition of Bcr-Abl, PDGFR, cKit 
and FIt3 protein kinases [13]. Unfortunately, long term use of imatinib in some 
late stage GIST or CML patients may cause drug resistance leading to therapeutic 
failure. The dynamically complex oncogenic signaling network of cancer cells 
is able to “escape the addiction” of the Bcr-Abl oncogene as it becomes mutated. 
Furthermore, tyrosine kinase inhibitors cannot completely eradicate leukemic stem 
cells; both of these factors facilitate the progression of tumors [13]. Luckily, next 
generation tyrosine kinase inhibitors are available for imatinib resistant patients 
[13]. The broad-spectrum protein tyrosine kinase inhibitor Dasatinib (Sprycel®) 
not only binds to the mutated Brc-Abl kinase but also to Src tyrosine kinase. Despite 
the reduced selectivity of this inhibitor, the Src kinase family is also responsible for 
tumor progression, and their overexpression has been linked to several malignan-
cies [13]. Nilotinib (Tasigna®) is another tyrosine kinase inhibitor, which shares 
imatinib’s narrow tyrosine kinase selectivity profile, it inhibits the mutated Brc-Abl 
kinase activity, and is more efficient when compared to imatinib [13, 16]. Although 
lifelong therapy is expected with these next generation tyrosine kinase inhibitors, 
they are reported to achieve longer response rates [13, 16]. The FDA has approved 
both agents for first line use in patients with Ph positive CML in the chronic phase 
and for patients with resistance to imatinib [17]. Another dual Src and Bcr-Abl tyro-
sine kinase inhibitor called bosutinib (Bosulif®) has also been approved by the FDA 
for patients with Ph positive CML that have been treated with both imatinib and 
next generation tyrosine kinase inhibitors. It has been reported to have a superior 
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molecular response profile relative to imatinib in terms of inhibition potency to 
Bcr-Abl mutated tyrosine kinase and more selectivity, thereby decreasing its toxic-
ity profile [18]. Imatinib indicated for GIST patients has partial response rates and 
differs between subset populations depending on the cKit point mutation. Imatinib 
is able to extend patient life but resistance usually emerges due to modified point 
mutations in the cKit gene on GIST stem cells, or mutations in other oncogenes and 
enhanced drug efflux transporters. A second line broad-spectrum tyrosine kinase 
inhibitor Sunitinib (Sutent®) is indicated for imatinib resistant GIST patients. This 
is a multi-target inhibitor that affects vascular endothelial growth factor receptor 
(VEGFR) and PDGFR protein tyrosine kinases; it has also been approved for the 
treatment of advanced renal cell carcinoma [13].
Most cell surface growth factor receptors have tyrosine kinase activity, and play 
an important role in cancer pathogenesis. One of the most notable for molecular 
targeted signal transduction cancer therapy is epidermal growth factor receptor 
(EGFR/ ErbB1/ HER1). It is a member of the epidermal growth factor receptors fam-
ily (ErbB) of protein tyrosine kinases, which also include ErbB2/HER2, ErbB3/ Her3, 
and ErbB4/ Her4. Binding of a complementary ligand to these receptors induces 
receptor homo/hetero dimerization and subsequent tyrosine auto-phosphorylation, 
leading to activation of various downstream signaling molecules. In various types 
of cancers, the expression/activity profile of these receptors is increased leading to 
enhanced cell proliferation. Oncogenic mutations within the receptor kinases of this 
family have also been found in epithelial tumors, breast carcinomas, gliomas (glio-
blastoma multiforme) and in the case of EGFR in 10% of patients with non-small 
cell lung carcinoma (NSCLC) [13]. Currently, there are two FDA approved selective 
EGFR tyrosine kinase inhibitors gefitinib (Iressa®) and erlotinib (Tarceva®) and 
are indicated as first line therapy for NSCLC patients [13]. Initially, the response 
rates in patients after administration were not as efficient as expected, and it was 
later determined that the presence of EGFR overexpression alone does not predict 
effective therapy [13]. Instead, patients with particular types of EGFR substitution 
mutation, such as L858R mutation in the kinase domain are more likely to benefit 
from anti-EGFR therapy [13]. This was concluded from several clinical trials carried 
out on NSCLC patients comparing the administration of gefitinib to docetaxel in 
patients pretreated with platinum-based chemotherapy [19, 20]. Results of the trial 
concluded that gefitinib was either equally effective [19] or more effective [20] than 
docetaxel. A latter trial was conducted on patients of non-smoker Asian origin, and 
it was determined that they had a higher incidence of harboring the specific activat-
ing mutations in the EGFR kinase domain [13, 20]. Docetaxel is a well-established 
conventional chemotherapeutic agent which reversibly binds to microtubules with 
high affinity leading to inhibition of mitotic cell division. It is administered intrave-
nously, and has been reported to cause dose-limiting toxicity and adverse effects of 
grade 3 and 4 neutropenia in 30% of patients, as well as edema and other common 
side effects shared by conventional chemotherapies [21]. Gefitinib, on the other 
hand, is administered orally, with reported adverse effects of grade 1 and 2 diarrhea 
and skin rash [22]. Therefore, in terms of patient compliance, therapy with gefitinib 
has greater efficiency than chemotherapy with docetaxel even if they provide the 
same therapeutic efficacy, since there is a lower incidence of severe adverse effects 
and oral administration is preferred over intravenous administration. Another 
important aspect is that not all EGFR mutations in the kinase domain are sufficient 
to determine patient response and instead only patients with specific EGFR muta-
tions can benefit from certain molecular targeted treatments. In the case of gefitinib, 
the use of genetic screening is required prior to treatment. This prerequisite high-
lights the application of precision medicine in targeted cancer therapy and the need 
for diagnostic strategies involving prognostic biomarkers and tumor genotyping to 
Tumor Progression and Metastasis
6
determine the choice of targeted therapeutic. Manufacturer AstraZeneca, of gefi-
tinib as Iressa® had partnered with Qiagen to provide FDA-approved Therascreen® 
EGFR companion diagnostic test to identify eligible patients for this treatment, once 
they test positive for the specific EGFR substitution mutations [22].
Another member of the ErbB receptor family, HER2, has received wide recogni-
tion as a target for breast carcinoma, since it has been found to be upregulated in 
20–30% of breast cancers [23]. HER2 tyrosine kinase activation is initiated by homo 
or hetero dimerization with other ErbB receptors, in turn phosphorylation leads to 
signaling through two main downstream cascades, phosphatidylinositol 3 kinase 
(PI3K)/Akt and mitogen- activated protein kinase (MAPK); both predominantly 
involved in promoting cell growth and survival [13, 23]. The first FDA approved 
targeted monoclonal antibody (Mab) for cancer was transtuzumab (Herceptin®), 
which interacts with the extracellular domain of HER2 (with high affinity) and is 
known to be one of the most successful recombinant humanized anti-ErbB- receptor 
family antibodies [13]. The advantage of transtuzumab as an antibody, over previ-
ously mentioned small molecular targeted therapies, is that it exerts its cytotoxicity 
by several mechanisms as well as binding to the extracellular domain of HER2 on 
cancer cells with high affinity. Antibodies generally bind to their complementary 
receptor with higher selectivity or even specificity compared to small molecule 
therapeutics. Transtuzumab binds HER2 on the surface of cancer cells with high 
affinity to hinder HER2 dimerization. This also leads to degradation of the recep-
tor and prevents HER2 recycling. As a result, downstream signaling cascades 
of PI3K and MAPK are diminished, promoting cell-cycle arrest and apoptosis. 
Furthermore, transtuzumab is able to modulate the immune system by inducing 
antibody-dependent cellular cytotoxicity (ADCC) through its Fc domain [13]. It can 
also bind to Fc receptors on various immune cells, markedly natural killer cells, but 
also neutrophils, mononuclear phagocytes, macrophages and dendritic cells leading 
to immune cell recruitment to the tumor tissue. Cytotoxicity is mediated in various 
ways, natural killer cells inhibit cell proliferation and intratumoral angiogenesis by 
the secretion of cytokines and chemokines, and they also promote tumor immuno-
genicity by inducing the expression of major histocompatibility antigen on cancer 
cells [13]. Macrophages and phagocytes carry out phagocytosis by engulfing and 
eliminating tumor cells [13]. Complement dependent cytotoxicity is mediated after 
an antibody bound to the surface of a tumor cell also binds to a nearby complement 
protein C1q. This activates a series of enzymatic cascades in the classical complement 
pathway, ultimately facilitating the formation of a cytolytic membrane attack com-
plex on the surface of tumor cells in the form of pores that generate an influx of ions 
and water molecules leading to tumor cell lysis [13]. Transtuzumab has also been 
identified to play a role in the inhibition of angiogenesis by interfering with pro-
angiogenic and anti-angiogenic factors, and reverting tumor vasculature back into 
normal vasculature [13]. This is supported by the enhanced localization of paclitaxel 
in tumors during combination therapy with transtuzumab [24]. Unfortunately, one 
of the limitations of transtuzumab is that it is only able to block the dimerization of 
HER2 with unbound HER3. Consequently, dimerization of HER2 with EGFR and 
ligand-bound HER3 proceeds despite transtuzumab therapy, serving as one of the 
reasons of acquired resistance to transtuzumab. Concurrent therapy with another 
Mab pertuzumab (Perjeta®) is sometimes administered as it targets dimerization 
of HER2 with neuregulin ligand bound HER3 [13]. Resistance may also develop by 
mutations that prevent the complementary binding of transtuzumab to the HER2 
extracellular domain. For instance, proteolysis leading to mutated isoforms of HER2 
kinases, or elevation in the expression of Mucin-4 an O-glycosylated membrane 
protein that dimerizes with HER2 [23]. Overexpression of other ErbB members such 
as EGFR that are able to dimerize with HER2 is also common, in this case a small 
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molecule tyrosine kinase inhibitor lapatinib (Tykerb®), with dual action against 
HER2 and EGFR has been used [13, 23]. This further reinforces the challenges to 
treat patients with different molecular subtypes of breast carcinoma. As a result, 
transtuzumab is indicated for women that have been diagnostically found to strongly 
overexpress HER2 on their tumor cells and successful treatment response is more 
likely with early therapy. Transtuzumab has also been indicated as an adjuvant 
therapeutic particularly after surgery in order to eliminate micrometastases. It is also 
used in combination with various anticancer agents [13, 23, 24].
3.2 Hormone-based therapies
Various hormones are implicated in the pathogenesis of many forms of tumors 
such as breast, ovarian, and prostate. Hyperplasia and neoplasia can develop from 
excessive hormonal stimulation or loss of tumor suppressor genes that dictate hor-
monal secretions as they have a proliferating effect on target cells. Steroid hormone 
such as estrogen binds to estrogen receptors (ER) that belong to a superfamily 
of nuclear receptors. Upon binding, the receptor complex homo-dimerizes and 
interacts with sequence specific estrogen response elements in corresponding genes, 
leading to the activation of nuclear transcription factors that produce complemen-
tary mRNA. Elevated mRNA levels increase protein production in the endoplasmic 
reticulum, which ultimately result in various effector responses such as enhanced 
cell proliferation [25, 26]. While estrogen activity mainly regulates growth, devel-
opment and physiology of reproductive systems in both sexes, ERs are also found 
in neuroendocrine, skeletal, adipose and cardiovascular systems [25]. Estrogen 
signaling pathways are complex due to its nuclear and non-genomic influences, and 
downstream transcriptional activities affect the biological function of different tis-
sues expressing ERs [25]. Two types of ER have been identified ERα and ERβ, where 
ERα expression is considered the hallmark of hormone dependent tumor growth 
[25–27]. About 70% of breast cancer patients express the hormone receptors ER 
and/ or progesterone, making them susceptible to endocrine therapy [25–27]. These 
receptors have categorized breast cancer as intrinsic and molecular subtypes based 
on the genes the cancer cell expresses, and act as a blueprint for targeted breast can-
cer therapy [27]. The aim of hormone-receptor positive breast cancer therapy is to 
reduce the growth stimulatory effects of estrogen on breast cancer cells. A primary 
way to do this is by interfering with the ability of estrogen to bind to its receptor, 
via targeting estrogen receptors on breast cancer tumors that overexpress ER and 
competitively binding ERs to reduce the capacity for estradiol to bind. This concept 
actually paved the way for targeted cancer therapy, and was first demonstrated by 
the renowned non-steroidal derivative tamoxifen (Nolvadex®) [25–28]. After FDA 
approval in the 1970s, tamoxifen became one of the world’s best-selling hormonal 
cancer drugs largely relating to its efficacy and short-term safety profile relative to 
traditional chemotherapeutics at the time [28].
Tamoxifen is non-steroidal triphenylethylene derivative; it is classified as a 
prodrug, since its metabolites have a more pronounced effect on ERs [25, 28]. 
Tamoxifen and its metabolites act as selective estrogen receptor modulators 
(SERM) since they have both anti-estrogenic and pro-estrogenic activity contin-
gents on the target tissue [25, 28]. On mammary epithelia, tamoxifen is able to bind 
competitively to ERα thereby disrupting the binding of estrogen and inhibiting 
the transcription of estrogen responsive genes that ultimately antagonize hor-
mone dependent breast cancer cell proliferation and tumor development [25, 28]. 
Tamoxifen is metabolized hepatically by cytochrome P450 (CYP450) isoforms into 
pharmacologically active metabolites 4-hydroxytamoxifen (4-OHT), N-desmethyl 
tamoxifen and endoxifen. These metabolites have a higher affinity for ERs. 4-OHT 
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binds to ERs in breast tissue with an affinity similar to that of estradiol and inhibits 
ER-mediated gene transcription by recruiting co-repressors that modulate gene 
expression [29]. Their anti-tumorigenic activity is attributed to induction of 
apoptosis by downstream ER signaling pathways, inhibition of mitogenic growth 
factors activity and reduction of angiogenesis [30, 31]. Literature has demon-
strated the complex mechanisms of action for tamoxifen and its metabolites and 
the difficulty in determining the molecule responsible for each mechanism, it is 
also hypothesized that the response to tamoxifen therapy is an aggregate of the 
parent and metabolites actions [29]. Pro-estrogenic activities of tamoxifen and 
its metabolites are demonstrated on bone density, as it decreases bone loss and 
inhibits osteoclasts in post-menopausal women but causes deleterious effects on 
bone density in healthy pre-menopausal women [32]. Another pro-estrogenic 
activity of tamoxifen and its metabolites is found in uterine epithelia, and it has 
been linked to endometrial cancer in some women restricting its use to 5 years 
and labeling tamoxifen as a carcinogen [25, 28]. Tamoxifen has been indicated for 
pre- and post-menopausal women and men diagnosed with hormone-responsive 
ER positive early stage breast cancer after surgery and as a chemopreventative for 
high-risk women [25, 27, 28].
Alternatives to SERMs exist, particularly for patients with advanced breast 
cancer or as a second line therapy to tamoxifen resistant tumors. These include 
selective estrogen receptor down regulators such as Fluvestrant (Faslodex®) [33]. 
Their molecular activity is also mediated by binding to ER, however, they function 
entirely as ER antagonists, causing downregulation and degradation of ER and 
ultimately inhibiting proliferation of estrogen dependent breast cancer cells. An 
advantage to the use of fluvestrant over tamoxifen as it is devoid of ER endometrial 
adverse effects [33]. It has been used in combination with docetaxel as it enhances 
the sensitization of breast cancer cells to chemotherapy [33].
Another group of endocrine therapy that has been indicated for postmenopausal 
women with hormone responsive ER breast cancer is aromatase inhibitor (AI) 
[26]. Their principle mode of action is to decrease circulating levels of estrogen and 
function by targeting and interfering with the enzyme responsible for the conver-
sion of androgens to estradiol. CYP450 enzyme complex aromatase is responsible 
for catalyzing the final step in the biosynthesis of estradiol in both pre and post-
menopausal women. In premenopausal women, the primary source of estrogen is 
from the ovaries, while in post-menopausal women adrenal and ovarian androgens 
are converted to estrogen by enzyme aromatase in peripheral tissues [26, 33, 34]. 
AIs have been categorized into two main groups, Type I and Type II inhibitors. 
Type I AIs are irreversible inhibitors of aromatase, they are also known as mecha-
nism based inactivators [26, 34]. These AIs are designed to mimic the substrate 
of aromatase androstenedione and are recognized by the enzyme as alternate 
substrates. Hence they undergo irreversible chemical reactions and are converted 
into intermediates during catalysis; the intermediate however, is reactive and 
causes inactivation of the enzyme [26, 33, 34]. A successful example of a steroidal 
AI inhibitor is exemestane (Aromasin) [26, 33, 34]. It is an inhibitor of human 
placental aromatase and has shown relatively prolonged reduction of estrogen levels 
(4-5 days) in postmenopausal women with breast cancer due to irreversible binding 
to aromatase [34]. Exemestane has been found to decrease hormone dependent 
mammary tumors in hormone receptor positive metastatic breast cancer [34]. Type 
II inhibitors act by non-covalent competitive binding to the active site of aromatase 
to decrease the amount of estrogen formed. These inhibitors are designed to target 
aromatase selectively in order to avoid binding to other CYP450 enzymes [26, 34]. 
They contain a triazole ring, which aids in their selective binding to the haeme iron 
of aromatase [26]. As the binding is non-covalent it is reversible, hence therapy 
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with these inhibitors must be continued [26, 34]. Non-steroidal examples of these 
AI include anastrazole (Arimidex®) and letrozole (Femara®), they are found to 
inhibit more than 95% of estrogen biosynthesis in post-menopausal women with 
advanced breast cancer [26, 34]. The FDA has approved the use of AI for postmeno-
pausal women diagnosed with hormone receptor positive breast cancer in the early 
stage as adjuvant therapy and for advanced and metastatic stages after tamoxifen 
treatment [26, 34].
3.3 Anti angiogenic therapies
Angiogenesis is a physiological process where new blood vessels are formed from 
preexisting mature vasculature [35]. This process allows the surrounding tissues 
to be supplied with nutrients and oxygen and simultaneously gets rid of metabolic 
waste products and carbon dioxide. In healthy tissue, angiogenesis is a temporary 
process and occurs during mensuration and embryogenesis, it is also an attribute 
of wound healing [35]. Prolonged angiogenesis however, is usually an indication 
of a pathogenic state such as cancer [35, 36]. The aberrant proliferation of cells 
during tumor formation in many types of cancers requires an extensive capacity 
of vasculature to manage the high demand in oxygen and nutrients and eliminate 
accumulated metabolic waste for tumor cells to grow and survive. Hypoxia in the 
tumor microenvironment leads to the production of hypoxia-inducible factor 1α; 
a stimulus for angiogenic switch, inducing the overexpression of pro-angiogenic 
factors mainly vascular endothelial growth factor (VEGF)- A, as well as fibroblast 
growth factor (FGF), placental growth factor (PlGF) and platelet derived growth 
factor (PDGF) by tumor and host cells [13, 35, 36]. Subsequently, proliferation of 
endothelial cells is stimulated and chemotaxis to tumor tissue facilitates the forma-
tion of the vascular lumen architecture and simultaneous disruption of surrounding 
vascular membrane structure [13, 36]. These factors contribute to the defective 
heterogeneous vasculature surrounding and within the tumor microenvironment, 
differentiating it from normal vasculature [35, 36]. Tumor vasculature has fenes-
trated blood vessels, with diminished pericyte coverage, and intratumoral blood 
vessels resemble immature perforated capillaries. As a result, vasculature is highly 
permeable, leaky, has poor blood perfusion and interrupted blood flow  
[35, 36]. Furthermore, the enhanced microvascular permeability leads to the 
aggregation of fibrin and other plasma proteins in the stroma of tumors, increasing 
the interstitial fluid pressure within tumors particularly in the absence of adequate 
lymphatic drainage [35]. This dynamically chaotic tumor microenvironment favors 
tumor progression in multiple ways. The high interstitial fluid pressure prompts the 
dissemination of tumor cells into intratumoral capillaries and neo-vessels providing 
a route for metastasis [36]. Elevated pressure in the tumor core resists the delivery 
of chemotherapeutics into these micro-regions of the tumor [35, 36]. The heteroge-
neous vascularization of the tumor microenvironment is dependent on the degree 
of angiogenesis inflected by tumor cells, so it can be different within and between 
tumor tissues, and obviously for different types of cancers [36]. These variations are 
amplified because intratumoral neo-vessel formation is mediated when pro-angio-
genic factors outweigh anti-angiogenic factors within the tumor microenvironment. 
Luckily, the differential activation of angiogenesis in normal tissue compared to 
tumor tissue provides a means of targeting this pathophysiology selectively, based 
on the phenotypic and functional differences between intratumoral vasculature and 
normal vasculature. Therefore, anti-angiogenic strategies serve as attractive cancer 
therapy; with the aim of terminating the blood supply to tumor tissues and micro-
regions in order to impose widespread hypoxia and necrosis selectively within solid 
tumors while sparing normal cells.
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The most extensively studied target to inhibit the angiogenesis process is the 
VEGF and its receptor (VEGFR). VEGF is a soluble glycoprotein with pro-angio-
genic activity, which is overexpressed in tumor tissue, and also by host fibroblasts 
and inflammatory cells. It is a ligand for the soluble and membrane bound tyrosine 
kinase VEGFR expressed on endothelial cells. Upon binding, a signaling cascade 
is activated leading to endothelial cell proliferation, maturation and migration to 
tumor tissue and neo-vessel formation. Different isoforms of VEGFR and ligands 
of VEGF exist; the most influential interaction for intratumoral angiogenesis is 
VEGF-A/VEGFR-2. The first and currently most successful anti-angiogenic cancer 
therapeutic approved by the FDA is the humanized monoclonal anti-VEGF-A 
antibody bevacizumab (Avastin®). It contains complimentary-determining regions 
of a mice antibody that selectively binds to circulating VEGF-A to neutralize it and 
inhibit its interaction with VEGFR2 [13, 35, 36]. Hence a unique feature of bevaci-
zumab is that unlike most antibodies that bind to receptors, it binds and traps the 
ligand VEGF-A, limiting its availability to bind to VEGFR2. This initially leads to 
vascular normalization, which involves reduction in the overall intratumoral vascu-
lature and hence limits the blood supply to tumors. The interstitial fluid pressure is 
lowered, hypoxia decreases and intratumoral perfusion is enhanced in the core of 
tumor tissues. Combination therapy is usually administered with bevacizumab to 
take advantage of the localization of chemotherapeutics deep into the micro-regions 
of solid tumors [35, 36]. Bevacizumab has been approved for the treatment of 
renal cell carcinoma, metastatic colorectal cancer, advanced NSCLC and recurrent 
glioblastoma [35, 36].
Another anti-angiogenic agent which has a similar mode of action to bevaci-
zumab is ziv-aflibercept (Zaltrap®), acts as a decoy receptor. It is a recombinant 
fusion protein designed by fusion of extracellular VEGF-A binding domain por-
tions of two isoforms of VEGFR (VEGFR1 & VEGFR2) with Fc portion of human 
IgG1 immunoglobulin [37]. Incorporation of the two VEGFR isoform binding 
domains in aflibercept allows this angiogenesis inhibitor to trap VEGF-A, VEGF-B 
and PlGF [36]. Although VEGF-B is not implicated in the stimulation of angio-
genesis, it is overexpressed in metastatic tumors and findings suggest it has a role 
tumor progression by maintaining existing vasculature, while PlGF is required for 
inflammation-associated angiogenesis in cancer progression. The FDA approves 
ziv-aflibercept for metastatic colorectal cancer in combination with chemothera-
peutic agents 5-Fluorouracil, irinotecan and leucovorin.
Many receptors that mediate angiogenesis are activated by the tyrosine kinase 
motif attached to their intracellular domain, most prominently is VEGFR, but also 
FGF and PDGR. Therefore, small molecule receptor tyrosine kinase inhibitors have 
been utilized as angiogenesis inhibitors; these include sunitinib (mentioned previ-
ously) and sorafenib (Nexavar®). Like sunitinib, sorafenib has multiple receptor 
tyrosine kinase inhibition activity, so its mode of action is not limited to the inhibi-
tion of angiogenesis, which it does by binding to VEGFR-1, VEGFR-2 and PDGF-B 
receptors, leading to morphological vascular normalization of tumor tissue [35, 36]. 
It also inhibits activation of signaling pathway Raf kinase (Raf/MEK/ERK) which 
is found to be activated in renal cell carcinoma among other cancer types, and 
c-KIT and Flt-3 kinases; also implicated in different cancer types [35, 36]. Multiple 
receptor tyrosine kinase inhibitors can be prescribed as mono-therapy since they 
act on multiple targets in cancer cells. In fact, their co-administration with chemo-
therapeutics was not found to improve the drug accumulation in tumor tissues [35]. 
However, it was found less likely to develop resistance to multiple tyrosine kinase 
inhibitors compared to selective single targeted anti-angiogenic therapies [36]. 
The opposite is true for bevacizumab and is the reason why it is co-administered 
with chemotherapeutic agents [35, 36]. During the initial phases of anti-angiogenic 
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therapy, the intratumoral vasculature undergoes vascular normalization. However, 
continuous administration of bevacizumab and several other anti-angiogenic 
therapies causes vascular shutdown and regional tumor tissue necrosis, leaving 
tumor cells adjacent to normal vasculature viable and prone to resistance [35, 36]. 
The turning point between vascular normalization and vascular shutdown for anti-
angiogenic therapies is called the normalization window and it is this duration that 
is found to provide optimal intratumoral drug accumulation of chemotherapeutics 
[35, 36]. Therefore, several factors are taken into account to maximize cancer 
therapy using angiogenic inhibitors. These include the type of cancer; whether 
it is dependent on angiogenesis, type of angiogenic inhibitor; hypertension is a 
common adverse effect for bevacizumab while multi-tyrosine kinase inhibitors can 
cause more adverse effects. The type of chemotherapeutic agent to insure it will be 
effective once accumulated in tumor tissues and will not counteract the angiogenic 
inhibitor. In addition to their temporal sequence and the time lapse between admin-
istrations that would define the normalization window; so that the chemothera-
peutic agent will be able to localized and accumulate within the tumor core after 
vascular normalization is induced by the angiogenic inhibitor to increase the overall 
tumor cell exposure to cytotoxic drugs [35, 36].
In order to define the vascular normalization window and success of anti-angio-
genic therapy, predictive detection of vascular parameters is required to enable 
precision and personal therapy for each patient. Microvascular density analysis is 
significant to determine vascular integrity during patient treatment and the sensi-
tivity of the cancer to anti-angiogenic therapy; it can be monitored in vivo by mag-
netic resonance imaging and vessel architectural imaging. These techniques have 
led to the finding that HER2-negative (triple negative) breast cancer patients have 
a variable response to bevacizumab therapy and the FDA withdrew its approval for 
breast cancer [35, 36]. Hypoxia detection is also a significant parameter to consider 
not only for angiogenesis but also since hypoxia is an indication of cancer aggres-
siveness, its metastatic potential and it can also contribute to tumor resistance 
particularly during radiotherapy. This parameter can be evaluated by monitoring 
oxygenation status during therapy. The use of positron emission tomography for 
hypoxia imaging has been implemented to select patients that will benefit from 
specific therapies. Tracers, biomarkers and genetically encoded fluorescent sensors 
have also been utilized as predictors of vascular normalization. Table 1 summarizes 
examples of molecular targeted therapeutic agents and the main target they affect.
The previous sections discussed targeted therapeutics based on their molecular 
mechanisms of action. Although many have proved successful and more efficient 
than conventional chemotherapeutics, there still remained limitations in terms of 
toxicity and resistance. The next section addresses a new field in targeted cancer 
therapy that aims to improve on molecularly targeted therapies by embedding 
further selectivity into therapeutics. The general principle behind this new and 
growing field is utilizing the selective delivery of therapeutics to target tumor tissue 
as well as the selective molecular mechanisms observed in molecularly targeted 
therapeutics. Targeted delivery therapeutics can be classified into passive target-
ing which takes advantage of the enhanced permeation and retention effects of 
the tumor microenvironment or active targeting, which is based on incorporating 
targeting moieties that will guide the cancer agents to their targets. The following 
section discusses these two categories in more detail.
3.4 Passive targeting delivery therapeutics
Chemotherapeutic agents are often low molecular weight molecules, with char-
acteristically unfavorable pharmacokinetic profiles usually having short half-lives, 
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large volumes of distribution in healthy tissue but suboptimal biodistribution 
in tumors. The systemic circulation also influences their plasma protein binding 
strength limiting the free drug available for therapeutic action. Polar, and low 
molecular weight chemotherapeutic molecules (less than 30 kDa) generally have 
short systemic circulation exposure as they are cleared by glomerular filtration in 
the kidneys. On the contrary, macromolecules are commonly recognized by macro-
phages and cleared from the circulation by the reticuloendothelial (RES) system in 
the liver. Both of these mechanisms of clearance pose a threat to the drug concen-
tration required to produce the desired therapeutic effect in tumor tissue. In turn, 
higher concentrations of these drugs that usually have a low therapeutic index, 
need to be administered making non-selective toxicity inevitable. Furthermore, the 
inability of conventional chemotherapeutics to sufficiently localize and accumulate 
in the core of tumors contributes to severe adverse effects and therapeutic resis-
tance, rendering many incompetents for cancer therapy.
Passive targeting of cancer therapeutics aims to improve the pharmacokinetic 
properties of anticancer agents and tailor them to take advantage of the charac-
teristics and architecture of the tumor microenvironment. The principle behind 
passively targeted chemotherapeutics is to design delivery systems with improved 
pharmacokinetic profiles complimentary to the tumor microenvironment. So that 
encapsulated chemotherapeutics can be transported in the circulation safely for 
longer durations with minimal toxicity to surrounding healthy tissue. Once they 
reach the tumor microenvironment they passively accumulate in tumor tissues 
and are released at therapeutic concentrations to exert their cytotoxicity against 
cancer cells. As mentioned previously, tumor vasculature is different from normal 
• Tyrosine kinase inhibitors:
 ○ Imatinib (Bcr-Abl/c-kit/PDGFR)
 ○ Dasatinib (Bcr-Abl/Src)
 ○ Nilotinib (Bcr-Abl)
 ○ Bosutinib (Bcr-Abl)
 ○ Sunitinib (VEGFR/PDGFR)
 ○ Gefinitib (EGFR)
 ○ Erlotinib (EGFR)
 ○ Sorafenib (VEGFR-1/2.PDGF-B/Raf/MEK/ERK)
 ○ Lapatinib (HER2/EGFR)
• Monoclonal antibodies:
 ○ Transtuzumab (HER2)
 ○ Bevacizumab (VEGF-A)
• Hormonal therapies:
 ○ Tamoxifen (ER)
 ○ Fluvestrant (ER)
 ○ Exemestane (aromatase enzyme)
 ○ Anastrazole (aromatase enzyme)
 ○ Letrozole (aromatase enzyme)
• Anti-angiogenic therapies:
 ○ Ziv-aflibercept (VEGF-A)
Table 1. 
Examples of molecular targeted therapeutic anticancer agents with their main target.
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vasculature. These variations have a unique impact on the behavior of substances 
in the vicinity of the tumor microenvironment; the phenomenon is known as the 
enhanced permeation and retention (EPR) effect of tumors. It is attributed to the 
abnormal vasculature and impaired lymphatic drainage in the tumor microenviron-
ment [37]. The imbalance in angiogenic factors and matrix metalloproteinases leads 
to the formation of highly disorganized dilated vessels with fenestrations, due to 
pores and wide gap junctions between endothelial cells that lack sufficient pericytes 
and a basement membrane [37]. Intratumoral vessels usually lack the smooth mus-
cle layer surrounding endothelial cells and hence remain dilated [37]. As a result, 
intratumoral vasculature is leaky enough to extravasate macromolecules >600 nM 
in diameter into tumor tissues as opposed to normal vasculature where tight junc-
tions restrict the permeability of molecules sized >4 nM [37]. Furthermore, the 
impaired lymphatic system in the tumor microenvironment retains extravasated 
molecules allowing them to accumulate [37]. Therefore, the enhanced permeation 
of macromolecules in neoplastic vasculature and their retention and accumulation 
into tumor tissues lead to the application of nanotherapeutics as delivery systems 
for targeted cancer therapy.
The design of delivery systems with improved pharmacokinetic profiles and 
biodistribution that complement the pathophysiology of the tumor microenviron-
ment is made possible by utilizing nanocarriers. The field of nanomedicine, derived 
from nanotechnology is extremely broad with a deluge of components synthesized 
and investigated for various diseased states. Nanocarriers are colloidal drug delivery 
systems with sizes in the nanometer range (generally <500 nM) imparting a high 
surface to volume ratio to them and their cargo. This is a significant feature for 
their characteristics. Variations in size, shape, and synthetic constituents have been 
investigated to determine the ideal nanocarriers for enhanced bioavailability and 
therapeutic efficiency of anticancer agents. The principle behind nanocarriers is to 
allow drugs to behave as though they have a larger molecular weight. Much research 
has gone into determining the ideal size of nanocarriers for cancer therapy and it 
was found to range from 10 to 100 nM [38]. Justified as nanocarriers >10 nM are 
more likely to escape rapid excretion by glomerular filtration in the kidneys. While 
nanocarrier >100 nM are more likely to be absorbed by proteins for opsonization 
prior to hepatic uptake and clearance by RES [38]. Surface charge of nanocarri-
ers is another modifiable property to manipulate the pharmacokinetic profiles of 
therapeutics. It is attributable to the various types of nanomaterial formulations 
available to synthesis these carriers. Neutral and anionic nanocarriers are favorable 
in evading renal elimination whereas cationic nanocarriers form better interactions 
with the negatively charged cell membrane and enhances their cellular uptake 
[38]. Another way to modify the surface of nanoparticles is by a process called 
PEGylation. It involves coating the surface of nanoparticles with an inert polymer 
polyethylene glycol (PEG) so that they are shielded from interactions during 
systemic circulation, particularly from protein blood components and even aggre-
gation with one another. This imparts stealth properties to nanoparticles and has 
been effective in increasing circulation times of nanoparticles as they avoid surface 
absorption and opsonization, reducing the frequency of clearance by phagocytosis 
and the RES system [39].
Nanocarriers can be categorized into 3 types based on their constituents, 
organic, inorganic, and hybrid [40]. Organic carriers include liposomes, solid 
lipid nanoparticles, dendrimers, polymer nanoparticles and polymeric micelles. 
Inorganic nanocarriers include carbon nanotubes and mesoporous silica nanopar-
ticles, while hybrids are a combination of both. This part of the chapter discusses 
the most prevalent organic nanocarriers as only two have been approved by the FDA 
to date for anticancer use.
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4. Organic nanocarriers
4.1 Liposomes
These microscopic lipid bilayers have become very popular after the success of 
the reformulated anticancer drug Doxil (Caelyx®) [41]. They are spherical vesicles 
with an aqueous core surrounded by single or multiple lipid bilayers, composed 
from natural or synthetic lipids such as phospholipids and cholesterol that can enter 
cells by endocytosis. The structure of liposomes allows them to encapsulate both 
water and lipid soluble drug payloads [41]. Schematic of liposome arrangement 
is shown in Figure 1. Hence liposomes can improve the pharmacokinetic proper-
ties of a range of drugs with different solubilities. Moreover, they can be coated 
with polymers or PEGylated to provide stealth properties. Doxil for instance is a 
polyethylene glycol coated liposome with the chemotherapeutic doxorubicin as the 
drug payload. Currently, it is the sole liposomal cytotoxic agent approved for solid 
tumors, and indicated by the FDA for ovarian cancer and multiple myeloma [41]. 
The chemotherapeutic doxorubicin is an anthracycline, which mediates its cyto-
toxicity by intercalating with DNA and inhibiting topoisomerase I and II activity, 
leading to apoptosis induction in cancer cells [42]. However, one of its main draw-
backs is cardiotoxicity which can be fatal or lead to congestive heart failure, hence 
patients are only permitted a limited dose in their lifetime [41, 42]. The reformula-
tion of doxorubicin as doxil has overcome this adverse effect; in fact, it has a very 
different toxicity profile from doxorubicin [41, 42]. While being dose limited by 
mucocutaneous toxicities, its adverse effects are much less severe. Furthermore, the 
bioavailability of doxil is preferential to doxorubicin as it is more stable in systemic 
circulation, has a longer half-life and slower clearance rate [42]. It is also able to 
extravasate into leaky intratumoral vasculature where its concentration is low com-
pared to normal vasculature where its concentration is higher, by passive diffusion 
and accumulate substantially more in solid tumors [42]. As a result, it has a better 
therapeutic efficacy and index compared to doxorubicin [42].
4.2 Nanoparticles
Nanoparticles have been synthesized in a variety of forms from various constitu-
ents. Solid lipid nanoparticles constitute organic solid lipids such as mono- di- and 
Figure 1. 
Schematic diagram of liposomal arrangement of phospholipid (not to scale).
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triglycerides, free fatty acids and alcohols or waxes and steroids [40]. These lipids are 
dispensed in water to form a nanosized colloidal dispersion with a large size range of 
50–1000 nM, an emulsifier is added to stabilize the formulation [40]. Lipid constitu-
ents offer great advantages as nanocarriers for anticancer drugs classified as class II 
and class IV in the Biopharmaceutical classification system, where aqueous solubility 
is low [40]. This is because they increase the solubilization of lipophilic drugs and 
enhance their bioavailability. These delivery systems also provide controlled drug 
delivery, they are biocompatible and biodegradable and have greater drug payloads 
as well as improved stability and are feasible for large-scale manufacture [40]. 
Another type of nanoparticles is polymeric nanoparticles these are solid nanosized 
colloidal particles that are formulated as nanospheres or nanocapsules depending on 
the structural organization [40]. They are made from both synthetic biodegradable 
polymers such as polylactic acid, polyglycolic acid, PEG and N-(2-hydroxypropyl) 
methacrylamide, or natural polymers such as albumin, alginate, collagen, chitosan 
and heparin [40]. The advantage of using polymeric nanoparticles is that they are 
usually biocompatible and biodegradable, hence reduce toxicity and are degraded in 
the body by normal metabolic routes [40]. They also offer greater drug stability in 
the circulation and during storage, are formulated to be homogenous compared to 
liposomes and retain the enhanced bioavailability characteristic of nanocarriers [40].
A successful example of an anticancer polymeric nanoparticle that has been 
approved by the FDA is Abraxane®, for the treatment of metastatic breast cancer 
and NSCLC. It constitutes the chemotherapeutic taxane paclitaxel bound to the 
natural polymer albumin in a solvent free formulation, forming a colloidal suspen-
sion of 130 nM particles. This formulation has several advantages over the use of 
the traditional chemotherapeutic paclitaxel limited by its poor aqueous solubility. 
Previously, paclitaxel was administered in a formulation with Cremophor® a 
solubilizing agent to enhance its solubility in the systemic circulation, however, many 
patients suffered hypersensitivity reactions from Cremophor® and pretreatment 
with steroids or antihistamine is recommended for these cases [43]. Albumin acts as 
a carrier for hydrophobic paclitaxel without Cremophor®, and is found to accumu-
late in tumors along with its bound constituents [42]. It is also able to enhance the 
endothelial cellular uptake of paclitaxel by the formation of caveolaes during trans-
cytosis, this is reflected in clinical trials where the permeation and antitumor activity 
of Abraxane® was higher compared to paclitaxel. It is also found to have a higher 
maximum tolerated dose and the adverse effects of Abraxane® were reported to be 
less severe and frequent than the general taxane associated adverse effects [41, 43].
4.3 Nanocarriers for gene therapy and smart delivery systems
The enhanced stability during systemic circulation offered by nanocarrier to 
their cargo has served as a key advantage to the application of targeted gene deliv-
ery for cancer therapy. Gene therapy has been implicated to replace or knock out 
mutations commonly detected in cancer or insert new genes into cancerous cells 
to induce apoptosis. Therefore, by targeting endogenous tumor gene expressions, 
a highly potent and specific therapeutic effect can be instigated with minimal 
off-target toxicity. This is widely applicable to cancer therapy due to its depen-
dence on oncoproteins and oncogenes. Moreover, multiple genes can be targeted 
to inhibit tumorigenesis, recurrence and resistance [44]. However, challenges 
with regard to toxicity and instability have rendered gene therapeutics immature 
for cancer therapy. The introduction of naked genetic material such as DNA, 
plasmid DNA, small interfering RNA, nucleotides, and peptides in the systemic 
circulation is limited due to instability and degradation by serum nucleases in the 
plasma as well as rapid renal clearance and phagocytosis by immune cells [44]. 
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In addition, not only is cellular uptake restricted but nuclear delivery of genes 
into non-dividing target cells is inefficient and discrepancies exist on long term 
incorporation of genetic DNA information into the host cell, as it is likely to have 
unforeseen implications on patient’s safety and toxic immune responses have 
been reported [44].
Nanocarriers have the potential to be delivery vectors for genetic material as 
cargo to their target tissue. Their versatility allows them to be designed in a manner 
that allows high gene delivery efficiency and payload capacity [44]. Genetic mate-
rial can be incorporated and attached into nanocarriers by electrostatic interactions 
or surface conjugation [44]. Cationic nanocarriers like liposomes synthesized from 
cationic and neutrally charged lipids are able to condense DNA, siRNA, nucleotides, 
peptides and proteins to form complexes of plasmid DNA lipids that self-assemble 
into lipoplexes. Similarly, polymer nanocarriers are able to form polyplexes with 
nucleic acids [44]. These complexes protect the genetic cargo from enzymatic 
degradation in the systemic circulation and aid in cellular interactions that facilitate 
endocytosis. Hence they are able to deliver their cargo intracellularly increasing the 
likelihood of efficient transfection.
Moreover, nanocarrier can be synthesized from polymers that are able to 
respond to specific stimuli based on physiochemical differences between cancer 
and non-cancerous cells, leading to the development of smart drug delivery systems 
[45]. Their aim is to reduce dosage frequency in a spatially controlled manner and 
facilitate the delivery and accumulation of the therapeutic system to the target 
tumor tissue. Followed by the release of anticancer agent at the specific location at 
a precise concentration based on internal or external stimuli [45]. Smart polymer 
nanocarriers can respond to stimuli such as changes in pH, enzyme configurations, 
redox reactions and light [45]. The application of passive targeted therapy in cancer 
has proved to dampen down adverse effects experienced with traditional chemo-
therapeutics. In addition, the improved pharmacokinetic profiles and enhanced 
efficiency of passive targeted cancer delivery systems has increased the response 
and survival rates of patients. However, this strategy of targeted cancer therapy is 
not devoid of challenges as non-selective toxicity and resistance remains to be an 
issue that impedes cancer therapy. Hence a further extension to passive targeted 
cancer therapy was explored that pioneered the birth of a different strategy for 
targeted delivery it is active targeted therapy and is discussed in the final section of 
this chapter.
4.4 Active targeting delivery therapeutics
Active targeting anticancer therapeutics aims to further increase the selectivity 
of chemotherapeutics to tumor tissue via delivery strategies through preferentially 
potentiating their affinity towards cancer cells and escalating endocytic internal-
ization. The principle mechanism of active targeted cancer therapy is based on 
receptor-mediated interactions. Their framework is established through targeting 
moieties such as small molecule ligands or antibodies that bind to receptor of 
proteins, sugars or lipids on the surface of target cells. As a result, these ligands 
act as delivery agents for the anticancer therapeutic system, prompting its tumor 
accumulation and enhancing its residence time.
Many of the same receptors targeted in molecular targeted therapeutics have 
been utilized as active targeted delivery therapeutics, imparting a second function-
ality to active targeted delivery cancer therapy, whereby one part of the system acts 
by targeted delivery and the other part mediates molecular mechanisms of cytotox-
icity. Commonly targeted cell surface receptors include EGFR and HER2. Widely 
explored cell surface receptors include folic acid receptor, transferrin, and prostate 
17
The Principles behind Targeted Therapy for Cancer Treatment
DOI: http://dx.doi.org/10.5772/intechopen.86729
specific membrane antigen [11]. The scope of this targeting strategy is endless and 
a heterogeneous array of targeting components have been utilized and reported as 
drug-targeting conjugates such as antibodies in antibody drug conjugates (ADC), 
proteins, peptiodomimetic and small molecules.
Much of the success of active targeted delivery therapeutics for cancer therapy 
has been achieved with ADC. They constitute extremely potent chemothera-
peutic agents that are not administered alone, due to their narrow therapeutic 
window and extreme non-selective toxicity, examples include maytansinoids and 
auristatins. Maytansinoids are second-generation microtubulin polymerization 
inhibitors similar to vinca-alkaloid traditional chemotherapeutics, that have been 
modified to bind to tubulin with >100-fold higher affinity [46]. The ADC trans-
tuzumab emtansine (Kadcyla®/T-DM1) has been synthesized with a derivative 
of maytansin (DM1) conjugated to transtuzumab, previously mentioned, a MAb 
for breast cancer patients that overexpress HER2. This design allows targeted 
delivery of a highly potent cytotoxic agent to tumor cells that express HER2 
with a favorable therapeutic window that would otherwise not be achieved by 
the cytotoxic agent alone. Many factors need to be taken into account with the 
design of ADC, particularly the binding affinity of the targeting ligand to the 
receptor after conjugation with the therapeutic agent, in the case of T-DM1, it 
binds to HER2 with a similar binding affinity to free transtuzumab [46]. This is 
not always the case as conjugation and linkers connecting the targeting moiety 
and therapeutic agent can cause steric hindrance or altered structural configura-
tions, which restricts or dissolves binding. Linkers are designed to stably carry 
the therapeutic system in systemic circulation and insure the therapeutic agent 
will not dissociate until it has reached the target site. This is achieved to a higher 
degree with non-cleavable linkers, but cleavable linkers are utilized more com-
monly as complete cleavage of the therapeutic agent from the system ensures 
efficient cytotoxic action. Binding of the targeting moiety to the receptor usually 
induces cellular internalization of the therapeutic system. Targeting moieties and 
linkers are also designed to facilitate intracellular release of the cytotoxic agent. 
Transtuzumab in T-DM1 aids in the internalization of DM1 into cancer cells, it 
contains a non-cleavable linker that keeps the system stable in circulation but 
may compromise the cytotoxic activity of DM1 if proteolytic lysosomal degrada-
tion of transtuzumab is inefficient [46]. In addition to the cytotoxic action of 
DM1 after intracellular release, T-DM1 is also able to inflect the antitumor action 
of transtuzumab regarding inhibition of HER2 signaling and marking HER2 
overexpressing cells for ADCC [46].
Although no small molecule active targeting delivery therapeutics for cancer 
therapy have been approved by the FDA to date, research in this field is growing 
exponentially. Many of these potential therapeutics in clinical stages of develop-
ment utilize nanoparticles that are decorated with targeting ligands on their surface 
and encapsulate anticancer drugs as payloads [11].
5. Conclusion
The origins of targeted therapy started by challenging cytotoxic chemotherapy 
with an alternative approach to treatment, achieved by adopting the “magic 
bullet” theory of selectivity between pharmacological principles of cancer and 
non-cancer cells. Targeted anticancer therapy is an exponentially growing class of 
chemotherapeutic agents with advantages over conventional anticancer drugs. The 
advantage is a result of selective targeting of cytotoxic agents towards cancer cells 
over normal cells. Selective targeting is based on variations in genes, proteins and 
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pathophysiology of cancer cells compared to non-cancerous cells. This has been 
explored and achieved in molecular mechanism therapeutics as well as passive 
and active targeting delivery strategies for cancer therapy. The progress in cancer 
therapy stems from the understanding cancer biology leading to detailed distinc-
tions between the pathophysiology of tumors and the physiology of normal tissue.
Strategies of targeted anticancer therapy have advanced by applying meticulous 
selectivity to chemotherapeutic. This commenced with variations in molecular 
mechanisms of action in mechanistic therapeutics with much success in targeting 
signal transduction pathways specifically tyrosine kinase proteins. Subsequently, a 
greater degree of selectivity is investigated by passive targeting mechanisms, which 
utilizes nanocarriers to take advantage of the enhanced permeation and retention 
effects of the tumor microenvironment. This strategy has also shown that not only 
is the pharmacodynamic profile of the anticancer agents significant for the success 
of cancer therapy but so is their pharmacokinetic profile. Further selectivity has 
also been explored by active targeting delivery via receptor-mediated interactions 
with cancer cells. All these targeting strategies can be combined and tailored to 
achieve efficient response rates for patients.
The application of targeted therapeutics has shifted therapy protocols for cancer 
patients towards precision medicine; hence various aspects need to be considered 
with targeting cancer therapy. This approach involves determining diagnostic 
biomarkers and genotyping tumors to choose the relevant targeted therapeutic for 
the patient. Furthermore, treatment needs to be designed and tailored for patients 
in terms of duration, dose and monitoring of adverse effects. Careful selection of 
combination therapies and dosing regimens are also critical to the success of cancer 
therapy.
Targeted cancer therapy has proven more effective than conventional chemo-
therapeutics as the maximum tolerated dose is higher so patients are able to tolerate 
therapeutic doses with less severe adverse effects. This resulted in improved patient 
response rates and survival. Although resistance is still an issue with cancer therapy, 
the strategies employed by targeted therapy have widened the scope of therapeutics 
available if resistance occurs. Although much of this field is still under develop-
ment, the progress made with targeted cancer therapy is changing the perspective 
of cancer from a fatal disease to a chronic one that can be managed throughout the 
patient’s lifetime.
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